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Do Cytotoxic Lymphocytes Kill
via Reactive Oxygen Species?
dA paper by Martinvalet et al. (2005) in this issue of
aImmunity examines the mechanisms used by gran-
zyme A to kill target cells after its cytoplasmic injec- c
tion by cytotoxic lymphocytes. They show that this n
protease induces mitochondrial damage and genera- f
tion of reactive oxygen species that are necessary for m
cell death. b
t
The current mechanistic paradigm for lymphocyte- s
mediated cytotoxicity is that perforin permeabilizes a
target cells to allow granzyme entry, and these prote- (
ases actually kill the target cell. For some years there
was intense focus on granzyme B, because its highly a
unusual specificity for substrate cleavage at aspartic p
oacid residues is similar to that of caspases, the endoge-ous suicide mediators. Granzyme B can directly trig-
er a caspase cascade by cleaving endogenous pro-
aspases in target cells, and it can also act indirectly
ia two pathways of mitochondrial outer membrane
amage: (1) cleavage of the Bcl-2 family protein Bid to
truncated form that potently attacks the outer mito-
hondrial membrane, and (2) cleavage of Mcl-1, which
ormally binds to and neutralizes Bim, another Bcl2
amily protein that attacks the mitochondrial outer
embrane. Damaging the mitochondrial outer mem-
rane causes the release of caspase pathway activa-
ors like cytochrome c from the intramembrane space,
o that granzyme B is clearly very effective in activating
target cell caspase cascade and subsequent death
Adrain et al., 2005).
Although textbook cartoons tend to make caspase
ctivation by granzyme B look like the dominant death
athway, several lines of evidence suggest that this is
nly one of multiple pathways used by cytotoxic lym-
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273phocytes to kill target cells. For one thing, why have
multiple granzymes of which only B has the critical “as-
pase” activity required for potent caspase activation?
Human blood NK cells are good killers but lack gran-
zyme B (Sayers et al., 2001). Knocking out granzyme B
in CTL and activated NK cells slows development of
target apoptotic features, but target lysis is only slightly
inhibited (Shresta et al., 1995). Furthermore, caspase
inhibitors shut down many of the apoptotic features of
target death mediated by CTL and NK cells, but the
targets still lyse on schedule (Sarin et al., 1998). Thus,
one or more alternative, caspase-independent death
pathways must also operate. Although one could say
they must be necrotic, this merely reignites the debate
about what apoptosis and necrosis really mean and
points out the need for molecular death pathways.
The paper from Judy Lieberman’s lab (Martinvalet et
al., 2005) in this issue provides good evidence that re-
active oxygen species (ROS) may be part of a caspase-
independent death pathway triggered by cytotoxic lym-
phocytes. ROS can be generated after damage to the
mitochondrial inner membrane accompanying the per-
meability transition, which seems to be one route for
releasing caspase activators from the intramembrane
space (Green and Kroemer, 2004). But it is generally not
clear if this type of mitochondrial damage in itself can
lead to the rapid death triggered by cytotoxic lympho-
cytes or whether caspases really do the job and the
crippled mitochondrial function and ROS generation
are an epiphenomenon. Thus it was hard to interpret
evidence for damage to the mitochondrial inner mem-
brane induced by granzymes B (Alimonti et al., 2001;
Thomas et al., 2001) and C (Johnson et al., 2003).
Martinvalet et al. (2005) extend these observations
to the other major granule protease, granzyme A. Like
granzyme B, introduction of granzyme A into the cyto-
plasm induced rapid production of ROS and loss of
mitochondrial membrane potential that was insensitive
to caspase inhibitors. But granzyme A did not induce
permeabilization of the mitochondrial outer membrane,
so apoptotic mediators from the intramembrane space
were not released, nor was the effect sensitive to bcl-2
expression. These results suggested that granzyme A
could induce cell death via a novel pathway pathway
involving ROS. Indeed, antioxidants and inhibitors of
mitochondrial permeability transition gave striking inhi-
bition of cell lysis, not only by granzyme A but also by
CTL. Here is evidence that ROS are not just an epiphe-
nomenon.
Both the hydroethidium signal and the ROS inhibitors
used make a case for superoxide anion involvement,
but superoxide reacts with a limited spectrum of bio-
logical molecules (Halliwell and Gutteridge, 1999), ar-
guing against a widespread oxidation of the cell inte-
rior. Follow-up studies could test whether superoxide
reacts with mitochondrial Fe-S proteins or nitric oxide,
but at this point the downstream components of this death
pathway remain undefined. ROS may also play critical
role(s) in the ultimate disposition of the dying cell. ROS
can activate pathways leading to degradation of target
cell DNA and promote phosphatidylserine flip (Kagan
et al., 2002), ensuring recognition and phagocytic
cleanup of target cells. Although some cell death path-ways in other cells show ROS production and attenua-
tion by antioxidants, their relevance is unclear because
cytotoxic lymphocytes kill so much more rapidly.
Martinvalet et al.’s results also suggest that ROS pro-
duction is required for nuclear localization of the SET
complex, components of which mediate granzyme
A-induced DNA fragmentation (Martinvalet et al., 2005).
The authors suggest that SET complex translocation is
an oxidative stress response and ROS might promote
nuclear colocalization of granzyme A and relevant sub-
strates. Generally, it would seem unlikely that nuclear
events would be relevant to rapid cell lysis, and CTL
effectors can readily kill enucleated targets. Neverthe-
less, ROS production in CTL targets may serve to en-
sure irreversible cell death accompanied by DNA de-
gradation.
One potential link between granzyme A-induced ROS
and cell death is a redox active protein in the SET com-
plex, Ape1/ref-1. Lieberman’s lab has previously shown
that Ape/ref-1 is a substrate for granzyme A, but not
granzyme B, and noncleavable forms protect from gran-
zyme A-induced cell death (Fan et al., 2003). A primary
function of ref-1 is maintaining reduced thiols and DNA
binding of transcription factors, such as AP-1, and ref-1
can inhibit intracellular ROS production. Thus, cleavage
of Ape/ref-1 by granzyme A may promote oxidative
stress and prevent repair of oxidative protein damage.
How this relates to cell death remains to be determined.
The Martinvalet et al. paper is significant because it
provides clear evidence that intracellular ROS production
is part of a cytotoxic lymphocyte-induced, caspase-inde-
pendent death pathway. More work is required before
this is firmly established and the downstream players
identified, but if one accepts the idea that heroic cyto-
toxic lymphocytes evolved mainly to fight off nasty in-
tracellular pathogens, it is satisfying to think the good
guys would evolve molecularly distinct, redundant
death pathways that together would beat any single in-
hibitors the bad guys might evolve.
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